glp-1 drugs trump Donald LIVE: Trump Announces Deal To Lower Cost Of Weight Loss Trump strikes deal to lower

The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality

Study Selection We selected pharmacokinetic studies of any injectable GLP1RA given with an oral medication, and product prescribing sheets reporting data without access to the original study

Weight Support*

It is ok to wear multiple PatchAid patches at a time

Considerations for employers who are thinking about covering GLP-1 drugs for weight loss.